UBS Group’s PDL BioPharma, Inc. PDLI Stock Holding History

UBS Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-500	Closed	-$4K	–	10175
2014 Q4	$4K	Buy	+500	New	+$3.96K	﹤0.01%	9192

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

UBS Group's PDLI Position: Q4 2020 in Review

UBS Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 84,455 shares — an estimated $266K sold.

UBS Group first reported a position in PDLI in Q4 2014 and held it in 24 quarters. The position peaked at $3.63M in Q4 2018. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

UBS Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
UBS Group sold 84,455 PDL BioPharma, Inc. shares in Q4 2020, an estimated $266K.
UBS Group first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 24 quarters.
UBS Group's PDL BioPharma, Inc. position peaked at $3.63M in Q4 2018.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.